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Abstract
Background: Predictive models of peptide-Major Histocompatibility Complex (MHC) binding affinity are important
components of modern computational immunovaccinology. Here, we describe the development and deployment of a
reliable peptide-binding prediction method for a previously poorly-characterized human MHC class I allele, HLA-Cw*0102.
Methodology/Findings: Using an in-house, flow cytometry-based MHC stabilization assay we generated novel peptide
binding data, from which we derived a precise two-dimensional quantitative structure-activity relationship (2D-QSAR)
binding model. This allowed us to explore the peptide specificity of HLA-Cw*0102 molecule in detail. We used this model to
design peptides optimized for HLA-Cw*0102-binding. Experimental analysis showed these peptides to have high binding
affinities for the HLA-Cw*0102 molecule. As a functional validation of our approach, we also predicted HLA-Cw*0102-
binding peptides within the HIV-1 genome, identifying a set of potent binding peptides. The most affine of these binding
peptides was subsequently determined to be an epitope recognized in a subset of HLA-Cw*0102-positive individuals
chronically infected with HIV-1.
Conclusions/Significance: A functionally-validated in silico-in vitro approach to the reliable and efficient prediction of
peptide binding to a previously uncharacterized human MHC allele HLA-Cw*0102 was developed. This technique is
generally applicable to all T cell epitope identification problems in immunology and vaccinology.
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Introduction
The products of the Major Histocompatibility Complex (MHC)
play a fundamental role in regulating immune responses,
modulating the functional development of lymphocyte subsets,
the acquisition and maintenance of self-tolerance, and the
activation state and responses of host immune defences. MHC
class I molecules expressed on the cell surface report on the
internal status of cells by presenting ligands for surveillance by
CD8+ T cells, natural killer T (NKT) cells and natural Killer (NK)
cells [1]. CD8+ T cells recognise antigen as short peptide
fragments complexed with classical MHC class I molecules [2].
NK cells express a diverse array of receptors that interact with
ligands including classical and non-classical MHC class I
molecules, which exert positive and negative influences on their
functions [3]. Human MHC class I molecules are both polygenic
and highly polymorphic [4]. This increases the chance that every
pathogen will contain many epitopes recognised by individuals
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within the population and places restraints on a pathogen’s ability
to escape immune control.
Characterisation of the peptides that are presented by MHC
molecules is of tremendous utility in basic research studies, and
can also have clinical applications. Identification of the ligands
recognised by T cells and NK cells facilitates analysis and
manipulation of lymphocyte subsets participating in host defence
and in disease processes, and can help mediate the development of
immune-based prophylactic and therapeutic strategies including
vaccines. Immunoinformatics, a newly emergent sub-discipline of
bioinformatics, addresses informatic problems within immunology,
such as the crucial issue of epitope prediction [5]. As high
throughput biology reveals the genomic and proteomic sequences
of pathogenic bacteria, viruses, and parasites, such prediction will
become increasingly important in the post-genomic discovery of
novel vaccines, clinical diagnostics, and laboratory reagents. Direct
laboratory-based analyses of T cell responses to overlapping
peptides drawn from pathogen proteomes are expensive in terms
of time, labour, and resource. The accurate prediction of peptide-
MHC binding provides a useful approach to candidate T cell
epitope selection since it allows the number of experiments needed
for their identification to be minimised. Database-driven models of
peptide binding include multivariate methods such as partial least
squares (PLS) and artificial neural networks [6,7,8,9].
To better understand the sequence-dependence of peptide-
MHC binding, we have taken a novel approach to exploring the
amino acid preferences of various human and mouse MHC alleles
[10]. Our approach to determining epitope-mediated immunoge-
nicity encompasses an integrated system comprising a state-of-the-
art database system known as AntiJen [11,12,13] and the
quantitative structure-activity relationship (QSAR)-based predic-
tion of binding to class I [14] and class II molecules [15], coupled
to integrated experimental validation [10]. We have deployed our
QSAR prediction models via MHCPred [16]; subsequently
supplementing this with sophisticated models of antigen presen-
tation [17]; deployed via EpiJen [18].
At the heart of our work is an immunoinformatic technique for
the prediction of peptide-MHC affinities, commonly known as the
additive method [19]. It is a two-dimensional quantitative
structure-activity relationship (2D-QSAR) technique whereby the
presence or absence of a group is correlated with biological
activity. For a peptide, the binding affinity is thus represented as
the sum of amino acid contributions at each position. Notably,
using cell surface MHC stabilisation assays to experimentally
determine peptide MHC binding affinities, we have used the
additive method to drive validation of our predictions and the
manipulation of peptide specificity for MHC alleles, leading to the
discovery of HLA-A*0201 superbinding peptides and potential
HLA-A*0201-presented epitopes which lack canonical anchors
[10].
Here we use similar methodology to characterise the peptide
binding specificity of the human MHC class I allele HLA-
Cw*0102. Study of the HLA-C alleles and the peptides they
present has received much less attention than work on HLA-A and
-B alleles. This is likely due to the fact that they are expressed at
lower levels on the cell surface than HLA-A and -B alleles [20],
and a higher proportion of CD8+ T cell responses are believed to
be restricted by HLA-B and HLA-A, with HLA-C a poor third
[21,22]. However despite this, HLA-C-restricted CD8+ T cell
responses can still constitute immunodominant components of the
host T cell response, and can exert significant immune pressure on
in vivo pathogen replication [23,24]. Further, in addition to
interacting with antigen-specific receptors on CD8+ T cells, HLA-
C molecules also interact with other activating/inhibitory
receptors that regulate the maturation and functions of lympho-
cyte subsets including NK cells, being more important than HLA-
A alleles and certain HLA-B alleles in this regard [3,25]. The
HLA-C1 group of alleles (to which HLA-Cw*0102 belongs)
interact with killer cell immunoglobulin-like receptors (KIRs),
specifically inhibitory receptors KIR2DL2 and KIR2DL3 and
activating receptor KIR2DS2, while the HLA-C2 group of alleles
interact with the inhibitory receptor KIR2DL1 and the activating
receptor KIR2DS1 [26]. The importance of HLA-C in the host
immune response, which was previously underestimated, is thus
now increasingly appreciated. This was emphasised recently by
results from a genome-wide association study of major determi-
nants of host control of HIV infection, which identified a
polymorphism located near to the HLA-C gene that is thought
to associate with differences in HLA-C expression levels as an
important determinant of set-point plasma viremia [27].
Unlike many HLA-C alleles, peptide binding to HLA-Cw*0102
has been investigated previously [23,28], but not with any great
rigour or precision. Barber et al. [29] combined results from pooled
sequencing of eluted cell-surface peptides and the sequencing of
individual peptides using Edman degradation, as confirmed with
tandem mass spectrometry, to propose a motif for HLA-Cw*0102.
Their reading of the data suggested strong amino acid preferences at
six of the nine peptide positions of the nonameric peptide. Guided
perhaps by a implicit structural understanding and precedents
established by other alleles, the motif presented at SYFPEITHI [30]
is much simplified: Ala and Leu at position P2 and Leu at the C-
terminus (P9) of the epitope peptide.
Sequence motifs are the oldest and currently still the best-known
tools for predicting the peptide-specificity of allele-dependent
MHC-peptide binding. Motifs are characterized by a few
dominant anchor positions with a very restricted set of allowed
amino acids. Such anchors are thought essential for binding. The
best-understood human MHC class I allele is HLA-A*0201 [10].
For a nonameric peptide, it has anchor residues at peptide
positions P2 (accepting Leu and Met) and P9 (accepting Val and
Leu). The motif method is admirably simple: it is easy to
implement either by eye or more systematically by using a
computer to scan through protein sequences. However simple
motif-based approaches are unable to provide complete or very
accurate predictions of the peptides able to bind to a particular
MHC class I molecule. Andersen et al. [28] used a semi-
quantitative cell-surface stabilisation binding assay for HLA-
Cw*0102 to measure the affinity of 20 peptides initially identified
using a motif modified from that of Barber et al. [29]. Of the 20
motif- positive peptides, only 12 exhibited measurable affinity.
Notably, the few HIV-1-derived CD8+ T cell epitopes restricted
by HLA-Cw*0102 that have been identified to date were
determined by screening of overlapping peptides. Using this
approach, Goulder et al [23] identified the octameric HIV-1 Gag
peptide VIPMFSAL as a T cell epitope. More recently, Liu et al.
[31] were able to identify several more HLA-Cw*0102-restricted
HIV epitopes: NSPTRREL, YSPLSLQTL, YCAPAGFAIL, and
HAPWDVNDL.
Due to the paucity of experimental data, peptide-binding
prediction methods for HLA-C including HLA-Cw*0102 have
received little attention, and, until recently, were not generally
available. As methods are developed that aim at extending
prediction beyond the small number of well-characterised MHC
class I alleles, several computational approaches have begun to
explore HLA-C in general and HLA-Cw*0102 in particular
[32,33,34,35]. In this study, rather than take a solely theoretical
approach, we sought to combine computational and experimental
methodologies, developing a hybrid in silico-in vitro algorithm for
Peptide Binding to HLA-Cw*0102
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peptide-HLA-Cw*0102 binding prediction. Using an in-house,
fluorescence-activated cell sorting (FACS) -based MHC stabiliza-
tion assay [36], we determined the binding affinities to the MHC
class I allele HLA-Cw*0102 of a set of 43 nonameric peptides. An
additive QSAR model was developed from this data, which we
used to reassess the preferred amino acids at each position and to
design new HLA-Cw*0102-binding peptides. Moreover, in
addition to undertaking in vitro tests, we used our model to try to
predict HIV-1 T cell epitopes restricted by HLA-Cw*0102.
Reactivity to the most affine of the candidate peptides (CAPAG-
FAIL) was subsequently observed in HIV-infected individuals,
confirming its status as a HIV-1 epitope.
Results
Development of an Additive 2D-QSAR Model for Binding
of Nonameric Peptides to HLA-Cw*0102
To generate data for use in developing a computational model of
peptide binding to HLA-Cw*0102, 43 peptides identified from the
work of Barber et al. [28] and Anderson et al. [23] (Table 1) were
assayed for binding to HLA-Cw*0102 using a FACS-based cell
surface MHC stabilisation assay [10,19]. This identified 25
peptides that bound to HLA-Cw*0102 with different affinities
(peptides 1–25, Table 1). The experimentally-determined pBL50
values ranged from over 7 to 3; peptides with pBL50 values below 3
were considered to be non-binders. From this set of binding
peptides, two models were generated using the PLS-based additive
method [19]: one containing just amino acid contributions and one
with contributions from both amino acids and side chain–side chain
interactions. The two additive models were roughly equivalent in
terms of statistical quality, so we applied the principle of Occam’s
razor and sought the simplest explanation, choosing the amino acid
only model. The amino acid only model was tested using cross-
validation: predicted peptide binding affinities are shown in Table 1.
The non-cross-validated parameters were r2 = 0.920 and standard
error of estimate (SEE) = 0.299. Leave-one-out cross-validation
(LOO-CV) gave q2 = 0.491, standard error of prediction (SEP) =
0.753, number of components (NC) = 2, and no outliers were
removed. These data are consistent with a robust model. Notably,
there was a trend for the experimentally-measured peptide binding
affinities to be slightly higher than the values predicted by the
model; potential reasons for this are discussed below.
The contributions made by different individual amino acids at
each position of a generalised nonameric HLA-Cw*0102-binding
peptide are presented in Figure 1. Favoured and disfavoured
binding residues, as defined by the model (applying a threshold of
.60.1), are shown in Table 2. The amino acids present at each
position in the nonameric peptide were found to impact in a positive
or negative fashion on peptide binding to HLA-Cw*0102. The
positions with the most pronounced effects on peptide-MHC
binding clustered at the N- and C-termini of the peptide sequence,
consistent with the observation that peptides bound to most MHC
class I molecules are typically anchored at or near their termini [37].
Design of Peptides Optimised for Binding to
HLA-Cw*0102
The model described above enumerates the effects of amino acid
residues at all positions of a nonameric peptide on peptide binding
to HLA-Cw*0102 (Table 2). It was used to design a set of peptides
optimised for HLA-Cw*0102 binding, and their MHC binding
affinities were then determined experimentally. The peptides
designed for optimal binding were prepared by combining preferred
amino acids at each position. For certain positions (1, 3, 5, 6) there
were single preferred residues, whilst other positions (2, 4, 7, 8, 9)
Table 1. List corresponding to the initial set of peptides used
in this study and their experimentally-determined and
predicted HLA-Cw*0102 binding affinities.
No. PEPTIDE Ref. pBL50(exp)
a pBL50(pred)
b
1 A A P A Y S R A L 21 5.751 6.010
2 F A P Y N K P S L 21 6.214 6.570
3 I T P T G T H P L 21 6.548 6.290
4 L P E T K F S E L 21 5.196 5.280
5 N A P W A V T S L 21 6.848 6.880
6 N C P E R I I T L 21 7.198 7.120
7 V A P W N S L S L 21 6.153 6.380
8 A Q P Q T T T P L 22 6.915 6.690
9 A T S P I V P S L 22 5.382 5.620
10 E V I P M F S A L 22 6.131 5.780
11 F A P G N Y P A L 22 6.723 6.510
12 I L R R P T S P V 22 5.099 5.110
13 I L S P L T K G I 22 3.061 3.410
14 I L S P R K E S V 22 4.764 4.680
15 I L S P R S E S V 22 5.581 5.050
16 I L S P R S K E S 22 3.534 4.460
17 I L S P S K E S V 22 4.944 4.390
18 L L T S P D V G L 22 4.933 5.140
19 L S P L T K G I L 22 5.421 5.050
20 L S P R S K E S V 22 6.041 6.330
21 L T S P D V G L L 22 4.563 5.180
22 P L S P P K K K D 22 4.996 5.350
23 S L E E C D S E L 22 3.426 3.770
24 V I P M F S A L S 22 5.610 5.440
25 Y A Q P Q T T T P 22 5.225 5.380
26 H L P E T K F S E 21 Non-binderC
27 A D A E K P F Y V 22 Non-binderC
28 A D D S H F V S I 22 Non-binderC
29 A V D A D D S H F 22 Non-binderC
30 D A D D S H F V S 22 Non-binderC
31 D L L T S P D V G 22 Non-binderC
32 G A D A E K P F Y 22 Non-binderC
33 G I P E P A H A Y 22 Non-binderC
34 I L K E P V H G V 22 Non-binderC
35 I L S R S K E S V 22 Non-binderC
36 I P E P A H A Y A 22 Non-binderC
37 K A T S P I V P S 22 Non-binderC
38 L L K L A S P E L 22 Non-binderC
39 L P S Q A M D D L 22 Non-binderC
40 L S P P K K K D L 22 Non-binderC
41 P L P S Q A M D D 22 Non-binderC
42 V D A D D S H F V 22 Non-binderC
43 Y M T P S S R P L 22 Non-binderC
aExperimental pBL50s measured using a FACS-based MHC stabilisation assay.
bCalculated pBL50s generated using the QSAR model described in the text.
CExperimental non-binders were initially predicted to be non- or low binding
peptides, but without useful discriminatory power.
doi:10.1371/journal.pone.0008095.t001
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had several acceptable amino acids. We selected favoured amino
acid residues from Table 2, combining all preferred residues to
generate new peptides. We chose Asn for position 1 (P1); Cys and
Gln for P2; Pro for P3; Glu and Gln for P4; Arg for P5; Ile for P6;
Glu, Ile and Thr for P7; Pro, Ser and Thr for P8; and Leu and Val
for P9. Combining preferred amino acids produced 256 peptides.
Peptide binding affinities were predicted, and the affinities of 4
distinct high binders were determined using flow-based MHC
stabilization assays (Table 3a). A good correlation was found
between the experimentally-determined and predicted affinities,
r2(pred) = 0.919. These peptides all bound strongly to HLA-
Cw*0102. However the binding affinities of these peptides did not
exceed substantially that of NCPERIITL, the most affine peptide
tested in the original peptide set (pBL50(exp) = 7.120). Additional
experiments were thus conducted to gain further insight into the
impact of amino acids at different positions in the sequence on
peptide binding to HLA-Cw*0102.
Use of Alanine Scanning to Explore Systematically the
Roles of Amino Acids at Different Positions in Peptide
Binding to HLA-Cw*0102
To explore systematically the relative contribution made by
amino acids at different positions in a nonameric peptide to HLA-
Cw*0102 binding affinity, a sequential alanine-scan of the peptide
NCPERIITL, which bound with high affinity to HLA-Cw*0102
(pBL50 = 7.12), was undertaken, whereby each of residues 1 to 9
was changed to alanine. The alanine-substituted peptides
(Table 3b) were synthesized and their binding to HLA-Cw*0102
was tested in flow-based MHC stabilisation assays. Interestingly,
although replacement of key MHC-interacting residues in a
peptide with alanine residues typically results in a non-trivial
decrease in the affinity of peptide binding to MHC, the predicted
HLA-Cw*0102-binding affinities of the alanine-substituted ver-
sions of the NCPERIITL peptide were not appreciably different
from that of the index peptide (Table 3b). Further, the
experimentally-determined binding affinities of these peptides
were also not substantially lower than that of the index peptide
(Table 3b). Only the conversion of Cys at position 2 produced a
marked change in peptide binding affinity: but the effect observed
was an increase in peptide binding affinity of 1.2 log units. These
results are consistent with the idea that the affinity of peptide
binding to HLA-Cw*0102 is determined by interactions made by
amino acids at all positions in the peptide sequence, rather than
being solely dependent on a single prominent anchor residue.
Figure 1. Relative contributions of different amino acids at each position to the interaction of a nonameric peptide with the HLA-
Cw*0201 molecule as determined using a QSAR-based additive model. The bar heights indicate the strength of the positive or negative
contribution made by each amino acid residue (denoted using the single letter code) at the indicated position (1–9) in a nonameric peptide to peptide-
MHC interaction. The contribution is equivalent to a position-wise amino acid regression coefficient obtained by PLS regression (as described in the text).
doi:10.1371/journal.pone.0008095.g001
Table 2. Summary of amino acids at each position that
favour or disfavour peptide binding to HLA-Cw*0102, as
defined by the QSAR model.
P1 P2 P3 P4 P5 P6 P7 P8 P9
Favoured
Binding a
N b C, Q P E, Q R I E, I, T P, S, T L, V
Disfavoured
Binding a
I, L L S P L S G, K E, G, L I, S
aAmino acids are included if they exceed a threshold of .60.10 as favoured or
disfavoured residues as shown in Fig. 1.
bAmino acids are highlighted in bold if they exceed a threshold of .60.20 as
favoured or disfavoured residues as shown in Fig. 1.
doi:10.1371/journal.pone.0008095.t002
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Exploration of the Contributions of a Diverse Range of
Amino Acids at Each Position to Peptide Binding to
HLA-Cw*0102
A potential shortcoming of our approach was that not every
amino acid was represented at each of the 9 possible positions in
the set of peptides used to generate the model – hence the positive
or negative influences of certain amino acids at particular positions
may have been overlooked. To gain insight into the extent to
which this may have affected the utility of the model, a set of 20
sequence-diverse peptides exploring different amino acids at
positions 1, 2, 4, 5, 6, 7, and 8 within the peptide were designed
(Table 3c). We chose positions 3 and 9 as pseudo-anchors (on the
basis of data in Table 2), and varied amino acids at all other
positions. A simple genetic algorithm [38] was implemented to
create peptide sequences. The genetic algorithm was constrained
using several criteria, such as the number of acidic and basic
residues in the peptide. Using the protocol outlined in [39], the
resulting large set of possible peptides was filtered using a
discriminant function model that aimed to partition binders from
non-binders. This model was built from the initial set of binders
and non-binders (as defined by their experimentally measured
affinities; see Table 1). The model generated scores for each
peptide which represented the probability that they would bind
rather than their affinity; thus a weak binder would score as well as
a strong binder. Missing values were set to be neutral and peptides
were ranked using their resulting binding score. For the top 250
peptides, diversity selection [40] was used to choose 20 sequence-
diverse peptides for testing (Table 3c). One peptide, with a
pBL50,3.00, was a non-binder; the rest exhibited appreciable
binding to HLA-Cw*0102 (Table 3c). We constructed a revised
affinity model including the new peptides. The non-cross-validated
parameters were r2 = 0.890 and SEE =0.271. LOO-CV gave
q2 = 0.421, SEP = 0.724, NC=3. While these results were
encouraging, the new model showed no marked improvement
over the original model. Nonetheless, our approach [39] can draw
strong validation from these findings: a very high proportion of
peptides were found to bind, and the use of multiple cycles of this
strategy should allow large numbers of affine peptides to be
discovered efficiently.
In Silico Discovery of Novel HIV Epitopes
As a test of the utility of our model for prediction of HLA-
Cw*0102-binding peptides in a pathogen sequence that may
constitute T cell epitopes, we sought to identify HLA-Cw*0102-
binding peptides in the sequence of HIV-1 and to determine
whether any of these were recognised by the virus-specific T cell
response in HLA-Cw*0102-positive individuals infected with this
virus. Two full-length HIV-1 proteome sequences were analysed
for peptides with predicted high binding affinity for HLA-
Cw*0102: the 2001 Clade B consensus sequence (a virtual
sequence representing the most frequently observed amino acids
at each position in multiple sequence alignments of HIV isolates)
and the sequence of the clade B virus HXB2 [41]. Twenty-two
unique peptides were predicted to possess predicted pBL50 HLA-
Cw*0102-binding affinities in excess of 5.0, which was deemed
sufficient for them to be potential T cell epitopes [10]; see Table 4.
These twenty-two peptides were evaluated using the flow-based
HLA-Cw*0102 binding assay, and half were found to demonstrate
measurable HLA-Cw*0102 binding (Table 4). We discuss a
number of possible reasons for the lack of demonstrable binding of
the other peptides below.
We then tested whether any of these HLA-Cw*0102-binding
peptides were recognised by virus-specific T cells from HIV-1-
infected individuals. Peripheral Blood Mononuclear cells (PBMCs)
from 5 HLA-Cw*0102-positive individuals chronically-infected
with clade B viruses were screened for reactivity to the 11 peptides
using IFNc ELISPOT T cell assays. To conserve patient PBMCs,
the 11 peptides were initially split into 3 pools (Pool 1: peptides 1–
4; Pool 2: 5–8; Pool 3: 9–11). Two of the five subjects (patients 3
and 4) responded to Pool 1 (Figure 2a); and subsequent testing of T
cell reactivity to the 4 individual peptides within this pool
confirmed peptide 1 as the epitope sequence recognised by both
of these patients (Figure 2b). Peptide 1 was the HIV peptide with
the highest affinity of binding to HLA-Cw*0102 (CAPAGFAIL;
pBL50 = 8.0). In order to assess the avidity of the patient T cell
Table 3. Test sets of newly-designed peptides.
No. Peptide pBL50 (pred)
a pBL50 (exp)
b
(a) Optimized binders
1 NCPEGYTSL 7.159 7.140
2 NEPQRIEPL 7.051 7.017
3 EQPERYESV 6.947 6.879
4 ECPQGITPV 6.954 6.962
(b) Alanine Substitutions
NCPERIITL 7.120
5 ACPERIITL 6.941 6.734
6 NAPERIITL 7.020 8.503
7 NCAERIITL 6.717 6.363
8 NCPARIITL 6.924 6.943
9 NCPEAIITL 7.097 6.714
10 NCPERAITL 6.975 6.613
11 NCPERIATL 6.963 6.696
12 NCPERIIAL 7.097 6.852
13 NCPERIITA 6.907 6.590
(c) Exploring Amino Acid Contributions
14 YMPTASCDL - 7.89
15 WAPHTDTSL - 7.90
16 VAPQLTFGL - 7.79
17 LGPEKLQYL - 6.82
18 MQPSRGKTL - 6.77
19 HMPDVGCIL - 6.75
20 SWPMQFDAL - 6.57
21 CMPDWLDRL - 6.48
22 TDPWFHRSL - 6.47
23 EFPWVFIEL - 6.45
24 CAPREPHVV - 6.42
25 EAPMWDHWL - 6.31
26 HNPGIATPV - 6.18
27 FMPIMKNEV - 6.17
28 VIPMFSAL - 6.07
29 KSPLDIVNL - 5.72
30 WRPDVNMQL - 5.54
31 WGPGIIWAL - 5.44
32 VRPMRQWPL - 5.42
33 QYPKGDAWV - Non-binder
aCalculated pBL50s generated using the QSAR model described in the text.
bExperimental pBL50s measured using a FACS-based MHC stabilisation assay.
doi:10.1371/journal.pone.0008095.t003
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responses to this epitope, we also titrated the epitope peptide in
IFN-c ELISPOT assays using PBMCs from the responding
patients. In both individuals, the response to CAPAGFAIL had
an avidity of approximately 1028 M (Figure 3). Using our QSAR-
based model for prediction of peptide binding to HLA-Cw*0102,
we were thus able to identify a HLA-Cw*0102-restricted T cell
epitope in the human pathogen HIV-1 to which high-avidity
responses could be detected in a subset of individuals chronically-
infected with this virus.
Discussion
In this paper we have used a potent combination of in silico
prediction and in vitro verification to characterise the peptide
binding specificity of the previously poorly- characterised human
MHC molecule HLA-Cw*0102. A 2D-QSAR approach was used
to model binding of nonameric peptides to HLA-Cw*0102 [19].
We defined positive and negative contributions made to HLA-
Cw*0102 binding affinity by amino acids at all positions of the
nonameric peptide sequence. This model was employed to predict
four ‘‘optimised’’ HLA-Cw*0102-binding peptides, all of which
showed a high affinity of binding to HLA-Cw*0102. Alanine-
scanning was used to probe and weight the contributions to affinity
of amino acids at each position of a HLA-Cw*0102-binding
peptide. Furthermore, the importance of amino acids randomly
allocated at each position of the peptide was explored by
evaluating the experimentally-determined binding affinities of a
set of sequence-distinct peptides defined by discrimination of
binding and diversity analysis. Realising that prediction must be
verified both in vitro and ex vivo, we also validated the utility of our
approach by predicting HLA-Cw*0102-binding nonameric pep-
tides in the HIV-1 sequence, one of which was confirmed to be an
epitope recognised by virus-specific T cells in a subset of HIV-
infected HLA-Cw*0102-positive individuals.
MHC class I molecules demonstrate extensive polymorphism
across the human population, even at the HLA-C locus. Four
mechanisms are largely responsible for the creation of new MHC
alleles: point substitution, allele conversion, gene conversion, and
recombination. The size and diversity of the MHC repertoire is
problematic for immunoinformatics. One solution is to identify
supertypes [34,42], another is the development of methods that
directly infer the selectivities of uncharacterised alleles [33,43,44],
and another is the de novo use of molecular dynamics [45,46]. Here,
we used a combination of computational and experimental
approaches to develop a hybrid in silico-in vitro algorithm for
predicting peptide binding to the MHC class I molecule HLA-
Cw*0102. The analysis of poorly-characterised alleles, such as HLA-
Cw*0102, is important in this context as it allows such approaches to
be validated and calibrated. Moreover, the data-driven methods
devised here can yield important results in their own right.
Table 4. HIV-1 peptides predicted to bind to HLA-Cw*0102.
Peptide number a Peptide sequence HIV Position pBL50 (pred)
b pBL50 (exp)
c
Clade B consensus
Peptide 4 EVIPMFSAL Gag 167–175 5.728 6.13116
Peptide 5 VIPMFSALS Gag 168–176 5.44 5.61006
IVRMYSPTS Gag 273–281 5.211 Non-binder
FPISPIETV Pol 155–163 6.05 Non-binder
Peptide 6 LTEEKIKAL Pol 181–189 5.376 5.28447
Peptide 7 FQSSMTKIL Pol 315–323 5.117 6.15401
Peptide 8 LLRWGFTTP Pol 364–372 5.363 5.68929
IVIWGKTPK Pol 535–543 5.004 Non-binder
LVSAGIRKV Pol 706–714 5.344 Non-binder
PQSQGVVES Pol 860–868 5.058 Non-binder
VVPRRKAKI Pol 974–982 5.915 Non-binder
LITPKKIKP Vif 153–161 5.915 Non-binder
Peptide 10 LQILAIVAL Vpu 4–12 5.826 6.11562
Peptide 9 PVPLQLPPL Rev 70–78 5.335 5.50055
Peptide 1 CAPAGFAIL Gp160 218–226 5.116 8.00554
EQFGNKTIV Gp160 350–359 5.044 Non-binder
Peptide 2 RVRQGYSPL Gp160 703–711 5.208 7.06262
Peptide 3 IVTRIVELL Gp160 773–773 5.617 5.94945
HXB2 concensusd
Peptide 11 ELQAIYLAL Pol 633–641 5.529 5.90231
ELIRTVRLI Rev 11–19 5.031 Non-binder
NSTWSTEGS Gp160 397–405 5.46 Non-binder
NYTSLIHSL Gp160 637–645 5.077 Non-binder
aPeptide number used in subsequent ELISPOT experiments.
bCalculated pBL50s generated using the QSAR model described in the text.
cExperimental pBL50s measured using a FACS-based MHC stabilisation assay.
dPeptides listed here were unique to the HXB2 sequence.
doi:10.1371/journal.pone.0008095.t004
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The binding specificity of HLA-Cw*0102 has previously been
characterised by sequence motifs [28,29,30]. However, there are
many problems with the use of such motifs. The most significant of
these is that motifs are, fundamentally, deterministic. A peptide is
either a binder or is not a binder. Generally speaking, the presence
of anchors, frequently located at positions 2 and/or 9 of a
nonameric peptide, is deemed to be necessary, but not sufficient,
for high affinity binding [6]. Prominent roles for other positions,
typically 1, 3, and 7 (so-called secondary anchor residues) are also
commonly observed [47]. It is well-known that matches to motifs
produce many false positive peptides that fail to bind to MHC, and
are, in all probability, producing an equal number of false
negatives, although peptides predicted to be non-binders are
seldom screened. Hence, although motif-based approaches to
prediction of peptide MHC binding specificity have proven useful,
they are increasingly seen as inadequate. An alternative approach
that we have pursued in previous studies is to employ methods that
dissect the contributions of amino acids at all different positions of
the peptide (which tend to weight the positions equally) in order to
predict peptide-MHC interactions [6,7,9]. Likewise here, we
again used a QSAR-based approach to quantify the contribution
to HLA-Cw*0102 binding affinity made, on a position-wise basis,
by amino acids along the whole of a nonameric peptide. We found
that amino acids at all positions in the peptide could exert a
positive or negative influence on peptide binding to MHC, a
finding that highlights the complexity of peptide-MHC interac-
tions. This was further emphasised by our observation that a series
of alanine-scanning mutants of the high-affinity HLA-Cw*0102-
binding peptide NCPERIITL all bound to HLA-Cw*0102 with
affinities equivalent to or higher than those of the index peptide,
again suggesting that peptide binding to HLA-Cw*0102 is not
predominantly dependent on any single residue, but rather is
determined by multiple interactions between the peptide and
MHC molecule. These findings underline the shortcomings of
approaches based on simple motifs for prediction of peptide
binding affinities, and provide a rationale for the use of more
sophisticated and insightful alternative approaches such as the
QSAR-based method employed in this study.
Cross-validation of our 2D-QSAR-based model for peptide
binding to HLA-Cw*0102 indicated that it provided good
predictions of the HLA-Cw*0102-binding affinities of the peptides
in Table 1. As seen previously in our analysis of HLA-A*0201
[10], there was a trend for the experimentally-determined peptide
binding affinities to be somewhat higher than their predicted
binding affinities. Synergies operate between different peptide
positions, and this may help to explain the underestimated
affinities seen here and previously [10,48]. The observation that
many of the peptides had higher binding affinities than suggested
by a summation of amino acid contributions is an example of co-
operative enthalpy-entropy compensation [49]. It is now well
known that the balancing of intermolecular motion and enthalpic
interactions induces a non-linear amplification of binding affinity.
Intermolecular motion weakens the many non-covalent interac-
tions that stabilize a complex. As additional interactions are
introduced, intermolecular motion is damped. As a result, all
Figure 2. Analysis of the recognition of HLA-Cw*0102-binding
HIV-1 peptides by T cells from HLA-Cw*0102-positive HIV-
infected individuals. PBMCs from clade B HIV-infected individuals
were screened for responses to (a) pools of HLA-Cw*0102-binding
peptides (pool 1 = peptides 1–4; pool 2 = peptides 5–8; pool 3 =
peptides 9–11) or (b) individual peptides (1–4) by IFN-c ELISPOT assay.
The number of cells producing IFN-c in response to stimulation with
peptide(s) or medium alone is shown, expressed as the mean (of results
obtained in duplicate test wells) number of spot-forming cells (SFC) per
106 PBMCs. The error bars indicate 1 standard deviation above the
mean.
doi:10.1371/journal.pone.0008095.g002
Figure 3. Dose-response titration of the peptide CAPAGFAIL.
The responsiveness of T cells from two HIV-infected individuals to 10-
fold dilutions of the peptide CAPAGFAIL was assessed by IFN-c ELISPOT
assay. The results shown are the specific response elicited at each
peptide concentration, expressed as a percentage of the maximum
response (that elicited by 1025 M peptide) observed in the individual
concerned.
doi:10.1371/journal.pone.0008095.g003
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interactions are more favorable and the complex is more cohesive.
As an example, peptide 17 (Table 1) is a medium binder, while
peptide 35 is a non-binder, yet the sequence is the same except for
the substitution of an arginine in peptide 35 by a proline in peptide
17 at peptide position P4. Examination of Table 2 and Figure 1
indicates that proline at P4 results in an overall unfavourable
contribution to binding, while arginine makes a contribution
which is overall nearly neutral. On this basis, peptide 17 would be
expected to be a less good binder than peptide 17, whilst the
converse is in fact the case. This apparent albeit minor
inconsistency may be due to a cooperative or enthalpy-entropy
compensation effect.
Unfortunately, intrinsic error in the biological measurements
precludes construction of a predictive method that can effectively
factor-out these co-operative interactions. Instead, the signal is
suppressed within a low signal-to-noise ratio: use of a model with
more variables does not yield better statistics. There are a number
of factors that may limit the accuracy of the method used for
analysis of peptide-MHC binding affinity and prevent use of the
data to probe such subtle effects with confidence. In this context, it
is worth noting that the recognition of class I MHC molecules by
HLA allele-specific antibodies can be influenced by the identity of
bound peptides. It is thus possible that the Cw*0102-specific mAb
VP6G3 used in this study may bind to distinct peptide-MHC
complexes with different affinities in a peptide-dependent manner.
It was beyond the scope of the present study to evaluate such
binding in a fully quantitative manner. On the basis of other
studies such discrepancies are unlikely to be significant; yet we can
not dismiss this phenomenon, which may contribute to the noise
inherent within the biological observations and thus the impreci-
sion of any derived prediction method.
The QSAR-based model was used to predict four ‘‘optimised’’
HLA-Cw*0102-binding peptides. All of these showed a high
affinity of binding to HLA-Cw*0102, although their binding
affinities did not exceed those of the most affine peptide in the
original peptide set. This may have been because the
contributions of all amino acid types at all positions were not
adequately represented in the dataset used to generate the
model. This is a shortcoming common to traditional natural-
peptide-only analyses [6], which leads to highly biased and
restricted distributions of amino acids. Here, we explored the
role of different amino acids at positions throughout the peptide
by generating a set of sequence-diverse peptides and measuring
their binding to the HLA-Cw*0102 molecule. The overall model
comprising all affine peptides did not improve on the initial
model. There are many possible reasons for this. The set of
peptides may, as a consequence of its diversity, actually comprise
several subsets with distinct structure-activity relationships.
Measured binding may contain some element of cross- or non-
specific binding to other cell surface molecules. Nonetheless, the
high proportion of binders observed provides significant
validation for the efficiency of this approach. In future,
discriminant models - as well as affinity models – could generate
diverse peptide sets iteratively leading to more comprehensive
and robust QSAR-based models for peptide binding to HLA-
Cw*0102 or, more generally, for any allele.
To validate the utility of our QSAR-based model for prediction
of HLA-Cw*0102-binding peptides in a pathogen sequence that
may constitute epitopes recognised by the host immune response,
we tested the ability of the model to predict putative nonameric
HLA-Cw*0102-restricted T cell epitopes in the HIV-1 sequence.
There were several reasons for choosing HIV-1 as a test pathogen.
First, there is a strong rationale for identifying HIV-1 peptides
presented by distinct MHC class I molecules that may be
recognised by T cells and/or NK cells in vivo. Identification of
regions of the HIV-1 genome that are targeted by the immune
system is a valuable asset for basic research aimed at characterising
the host immune response plus viral immune evasion strategies
and identifying correlates of immune protection, knowledge that is
urgently needed to inform the development of new prophylactic
and therapeutic vaccination strategies to combat this infection
[50,51]. Second, HIV sequence data is readily available [41],
further, as a virus with a reasonably small (,9.2 kb) genome, it
was feasible to synthesise and test all the predicted HLA-Cw*0102-
binding peptides in the proteome. Given the extent of HIV-1
sequence diversity, we confined our analysis to work on clade B
viruses/virus-infected individuals, and predicted HLA-Cw*0102-
binding peptides in both the clade B concensus virus sequence and
the sequence of a ‘‘reference’’ clade B virus, HXB2. Finally, HIV-
specific T cell frequencies in healthy, viremic individuals are
typically high enough for responses to epitopes of varying
immunodominance to be detected ex vivo by standard immuno-
logical assays, facilitating screening of HLA-Cw*0102-binding
peptides for T cell recognition.
Eleven HLA-Cw*0102-binding nonameric peptides were iden-
tified in the HIV-1 clade B concensus and/or HXB2 sequences,
one of which, CAPAGFAIL, was shown to be recognised by HIV-
specific T cell responses of high avidity in two of the five HLA-
Cw*0102-positive individuals chronically infected with HIV that
we tested. Subsequent to the completion of this study, the same
nonameric sequence was also described as a HLA-Cw*0102-
restricted T cell epitope recognised in other HIV-infected
individuals [52]. It is notable that two of the eleven HLA-
Cw*0102-binding nonameric peptides we identified (peptides 4
and 5 in Table 4) contained an octameric sequence, VIPMFSAL,
that has previously been shown to constitute an epitope recognised
by the T cell response in HIV-infected individuals [23,31]. The
lack of recognition of peptides 4 and 5 by T cells from the HIV-
infected subjects we studied may reflect a lack of reactivity to this
epitope-containing region in these individuals or an inability of
VIPMFSAL-specific T cells to recognise complexes of the longer
peptides bound to HLA-Cw*0102. However, it is most likely to
result from the poor presentation of the VIPMFSAL-containing
nonameric peptides in our assays. Both peptides had moderate to
low HLA-Cw*0102 binding affinities and may have been out-
competed by endogenous peptides for presentation on PBMCs.
Studies in which HIV-specific T cell responses were mapped
empirically [23,31] have identified HLA-Cw*0102-restricted T
cell responses to additional HIV-1 clade B peptides that were not
identified as putative HLA-Cw*0102-restricted HIV T cell
epitopes in this study. Potential explanations are many. First, the
optimal sequences of some of these epitopes are not nonamers (and
our model predicts only nonameric HLA-Cw*0102-binding
peptides). Second, as discussed above, all models, including ours,
provide only moderately successful predictions of all potential
HLA-Cw*0102-binding peptides, hence the binding affinity of
certain peptides may have underestimated. Finally, a subset of
epitopes recognised by virus-specific T cells may bind to MHC
with very low affinity, and hence may not have been characterised
as HLA-Cw*0102-binding peptides by our model.
Had we been able to test more HLA-Cw*0102-positive
patients, we might potentially have identified T cell responses to
more of the HLA-Cw*0102-binding peptides in Table 4. The
epitopes targeted by the HIV-specific T cell response in a given
infected individual are determined by host factors - antigen
processing, the complement of HLA class I molecules expressed,
and the profile of T cell receptors in the repertoire (which will
have been modified by the infection and vaccination history of the
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subject, as well as by their individual genetics) - and also by the
sequence of the in vivo viral quasispecies, which not only varies
markedly from one infected individual to another, but also
undergoes considerable evolution within a given subject over time
[52]. In particular, detection of responses to those HLA-
Cw*0102-binding peptides in poorly conserved regions of the
viral proteome may require screening of a larger number of
subjects, as the test peptide sequences may not be well-conserved
in the viral quasispecies present in all individuals. It was notable
that the CAPAGFAIL peptide to which responses were observed
in two subjects was the HIV peptide that exhibited the highest
affinity of binding to HLA-Cw*0102 (Table 4). Responses to other
lower-affinity peptides may have been rarer and/or less
immunodominant, requiring screening of a large patient cohort
for their detection. The T cell responses we detected to the
CAPAGFAIL epitope were also of high avidity, so may have been
better-able to cross-recognise our test peptide in spite of sequence
differences to the autologous virus sequence than lower avidity
responses to other viral epitopes. The patient samples used to
screen for T cell responses to our HLA-Cw*0102-binding peptides
were derived from individuals chronically-infected with HIV, as
the breadth of epitope recognition in chronic infection is greater
than that in acute infection [54]. However given the increasing
evidence to suggest that there are differences in the epitopes to
which strong responses are detectable in the acute and chronic
phases of infection, with a subset of the initially-immunodominant
responses undergoing a rapid decline in frequency, due in part to
viral mutational escape and loss of the epitope sequence [55,56],
it would also have been of interest to determine whether responses
to additional HLA-Cw*0102-binding peptides were detectable in
acutely-infected individuals: unfortunately, suitable samples were
not available.
Another question of interest is whether any of the HLA-
Cw*0102-binding HIV-1 peptides we identified may form part of
a peptide-MHC complex recognised by NK cell receptors in HIV-
infected individuals. HLA-Cw*0102 is a HLA-C1 serogroup allele
that interacts with the inhibitory KIR2DL2/3 and activating
KIR2DS2 receptors [57]. In addition, HLA-C molecules act as
ligands for other NK receptors including ILT2 and CD160 [58].
Current thinking suggests that the peptide content of MHC class I
molecules may modify their interaction with activating and
inhibitory NK cell receptors, such that predominantly inhibitory
signals are delivered when NK cells interact with MHC molecules
presenting self peptides on normal body cells, but a more
activating balance of signals are delivered when NK cells interact
with MHC molecules presenting viral or stress peptides on
infected/transformed cells [59]. A recent study showed that a
HLA-Cw4-restricted HIV-1 CD8+ T cell epitope could also be
recognised by the NK cell receptor KIR2DL1 [60]; so by analogy,
it is possible that some of the HLA-Cw*0102-binding peptides we
identified in this study may constitute KIR2DL2/3 or KIR2DS2
ligands.
In conclusion, we have used a combination of computational
and in vitro techniques to illuminate the characteristics of peptides
presented by HLA-Cw*0102. We show how the analysis of a
relatively small number of peptides can power a predictive
algorithm capable of scanning a viral genome and identifying
binding peptides from which an epitope emerges. What we really
require are reliable high-throughput screening approaches able to
generate large-scale data sets, such as that recently reported by
Buus and co-workers [61]. However, and despite such caveats, we
have shown clearly that even with a relatively modest low-
throughput approach one can generate models with proven
utilitarian value.
Materials and Methods
Patients and Blood Samples
Individuals chronically infected (.6 months) with HIV-1 (clade
B) were recruited from the Centre for Sexual Health and HIV
Research (London, UK). Ethical approval for these studies was
obtained from the National Health Service Camden and Islington
Community Local Research Ethics Committee, and blood samples
were drawn with written informed consent. Patients were
asymptomatic and typically not receiving anti-retroviral therapy
at the time of sample acquisition. Blood was collected into acid
citrate dextrose or EDTA. PBMCs were separated by centrifuga-
tion over a Histopaque 1.077 density gradient (Sigma-Aldrich,
Poole, UK) and cryopreserved until needed.
HLA Class I Typing
DNA was isolated from patient PBMCs using a QIAamp DNA
Blood Mini Kit (Qiagen Ltd, Crawley, UK). HLA class I fine
typing was largely performed at the Churchill Hospital (Oxford,
UK) using a molecular PCR method employing sequence-specific
primer mixes.
Peptides
43 nonameric peptide sequences used in the study were
abstracted from Barber et al. [28] and Andersen et al. [23]
(Table 1). We tested only nonameric peptides, so overlapping
peptides were obtained where only longer peptides were reported.
All peptides used in this study were ordered either from
Mimotopes (Pensby, UK) or from the in-house peptide synthesis
service at the Institute for Animal Health (Compton, UK).
Peptide Binding Assay
Peptide binding to HLA-Cw*0102 was assessed using a FACS-
based MHC stabilization assay [62] with modifications as described
elsewhere [36]. This assay involves use of the transporter associated
with antigen processing (TAP)-deficient cell line T2, which has very
low levels of surface MHC class I expression due to the poor stability
of non-peptide-loaded MHC class I molecules. Incubation of T2
cells in the presence of peptides able to bind to one or more of the
MHC class I molecules expressed by these cells (HLA-A*0201,
HLA-B5 and HLA-Cw*0102) stabilizes their expression and results
in an increase in surface MHC class I levels that can be measured by
flow cytometry. In this study, a HLA-Cw*0102-specific antibody
was used to measure peptide-induced stabilization of HLA-C
expression on T2 cells, hence allowing evaluation of peptide binding
to HLA-Cw*0102. Briefly, T2 cells were incubated in 96-well flat-
bottom plates at 2x105 cells per well in a 200 ml volume of AIM V
medium (Life Technologies, Paisley, UK) with human b2-micro-
globulin at a final concentration of 100 nM (Scipac, Sittingbourne,
UK) with and without peptides at concentrations between 200 and
0.04 mM for 16 h at 37uC. Cells were then washed and surface
levels of HLA-Cw*0102 were assessed by staining with Cw*0102-
specific mAb VP6G3 [63] and a FITC-conjugated AffiniPure
F(ab’)2 fragment goat anti-human IgM Ab (Jackson Immunore-
search Laboratories, West Grove, PA, USA). Cells were fixed at 4uC
in 4% paraformaldehyde and analyzed on a FACSCalibur (BD
Biosciences, Oxford, UK) using CellQuest software. Results are
expressed as fluorescence index (FI) values. These were calculated as
the test mean fluorescence intensity (MFI) minus the no peptide
isotype control MFI divided by the no peptide HLA-Cw*0102-
stained control MFI minus the no-peptide isotype control MFI. The
half-maximal binding level (BL50), which is the peptide concentra-
tion yielding the half-maximal fluorescence intensity (FI) of the
reference peptide in each assay, was calculated and is presented as
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pBL50 (–logBL50). The peptide VIPMFSAL, which binds with high
affinity to HLA-Cw*0102, was used as a reference peptide [23].
Peptides with a pBL50 above 6.0 were designated as high binders,
between 4.5 and 6.0 as medium binders, between 3.0 and 4.5 as low
binders, and below 3.0 as non-binders.
Additive 2D-QSAR Method
Two models using the additive method were developed: the first
contained only the amino acid contributions (eqn. 1) and the
second contained both amino acid contributions and side chain –
side chain interactions (eqn. 2):
pBL50~constz
X9
i~1
Pi ð1Þ
pBL50~constz
X9
i~1
Piz
X8
i~1
Pi,iz1z
X7
i~1
Pi,iz2 ð2Þ
where the const accounts for the peptide backbone contribution,
P9
i~1
Pi is the sum of amino acid contributions at each position,
P8
i~1
Pi,iz1 the sum of adjacent peptide side-chain interactions, and
P7
i~1
Pi,iz2 the sum of interactions between every second side-chain.
Every peptide sequence was presented as a string of 0s and 1s with
a length of 180 terms (20 aa69 positions) or 6180 terms
(2069+2062068+2062067). A term is equal to 1 when a certain
amino acid or interaction at a certain position exists, and 0 when it is
absent. Columns containing only 0s were omitted. The pBL50 values
(dependent variables) were included in the matrix as a first column.
The partial least squares (PLS) method was used to solve this
matrix. PLS handles data matrices with more variables than
observations by forming new x variables, named principal
components, as linear combinations of the old ones and then uses
them as predictors of the biological activity. We used the PLS
method as implemented in the QSAR module of SYBYL6.9 [64].
pBL50 was put as a dependent variable. The scaling method was
set to ‘‘none’’. The column filtering was switched off. The optimal
number of components was found by leave-one-out cross-
validation. The predictive power of the model was assessed by
the cross-validated coefficient q2 and standard error of prediction:
q2~1{
P
i~1
pBL50 expð Þ{pBL50 predð Þ
 2
P
i~1
pBL50 expð Þ{pBL50 meanð Þ
 2 ;
SEP~
P
i~1
pBL50 expð Þ{pBL50 predð Þ
 2
n{NC{1
;
where pBL50(pred) is the predicted pBL50 of the excluded peptide
and n the number of peptides.
The non-cross-validated model was assessed by the explained
variance r2 and standard error of estimate:
r2~1{
P
i~1
pBL50 expð Þ{pBL50 calcð Þ
 2
P
i~1
pBL50 expð Þ{pBL50 meanð Þ
 2 ;
SEE~
P
i~1
pBL50 expð Þ{pBL50 calcð Þ
 2
n{NC{1
;
where pBL50(calc) is the calculated pBL50 of the non-excluded
peptide. The non-cross-validated model was used to predict the
binding affinity of newly designed peptides.
IFNc ELISPOT Assay
Multi-Screen plates (MAHAS4510, Millipore Ltd, Watford, UK)
were coated overnight at 4uC with 5 mg/ml anti-human IFNc
capture antibody 1-D1-K (MabTech AB, Nacka, Sweden) in PBS.
Plates were washed 3 times with sterile PBS and blocked with 10%
heat-inactivated pooled human serum (PHS) (Sigma, UK) in RPMI
(sterile filtered) for 1 hr at 37uC in 5% CO2. Patient PBMCs were
thawed and washed 3 times in RPMI supplemented with 15% FCS
(Invitrogen Life Technologies, Paisley, UK), and then resuspended in
RPMI containing 5% PHS and dispensed into plates at 26105 cells/
well in a 100 ml volume. Cells were stimulated in duplicate with
medium only, PHA (Sigma-Aldrich, Gillingham, UK) at 10 mg/ml or
specific peptide at 1025 mM in a final volume of 120 ml for 1 hour at
37uC in 5% CO2. 30 ml of filtered FCS was then added to each well
and the plates were incubated at 37uC in 5% CO2 for 16–20 hours.
Plates were washed 3 times with PBS/0.05%Tween-20 and
incubated for 2 hours at 37uC in 5% CO2 with 1 mg/ml biotinylated
anti-human IFNc detection antibody 7-B6-1 (MabTech AB) in PBS.
Plates were then washed 3 times with PBS/Tween-20 prior to a 1-
2 hour incubation at room temperature with a 1/1000 dilution of
alkaline phosphatase anti-biotin (Vector Laboratories, Peterborough,
UK) in PBS/Tween-20. Following washing, enzyme activity was
detected using an alkaline phosphatase conjugate substrate kit (Bio-
Rad, Hemel Hempstead, UK) following the manufacturer’s protocol
and plates were incubated at room temperature for 30 minutes. The
reaction was stopped by rinsing the plates 3 times in tap water. Plates
were air-dried and spots enumerated using an AID image analysis
system with AID ELISPOT software version 2.5 (Autoimmune
Diagnostika GmbH, Strassberg, Germany). A positive response was
defined as one where the average number of spot forming cells was at
least twice the background number of SFC in medium alone wells
and exceeded 20 spots per 106 PBMC.
Acknowledgments
We are extremely grateful to the patients who consented to give samples for
this study, and would also like to thank Andrew Worth for his valued
management of flow cytometry facilities.
Author Contributions
Conceived and designed the experiments: ID PB DRF. Performed the
experiments: vAw MW IKM ELT. Analyzed the data: vAw CKH ID IKM
ELT PB DRF. Contributed reagents/materials/analysis tools: AM FC PP
JT IW. Wrote the paper: ID ELT PB DRF.
References
1. Heinonen KM, Perreault C (2008) Development and functional properties of
thymic and extrathymic T lymphocytes. Crit Rev Immunol 28: 441–466.
2. Jensen PE (2007) Recent advances in antigen processing and presentation. Nat
Immunol 8: 1041–1048.
Peptide Binding to HLA-Cw*0102
PLoS ONE | www.plosone.org 10 November 2009 | Volume 4 | Issue 11 | e8095
3. Bashirova AA, Martin MP, McVicar DW, Carrington M (2006) The killer
immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu
Rev Genomics Hum Genet 7: 277–300.
4. Hauptmann G, Bahram S (2004) Genetics of the central MHC. Curr Opin
Immunol 16: 668–672.
5. Flower DR (2008) Bioinformatics for Vaccinology. Wiley-VCH, 302 p.
6. Doytchinova IA, Flower DR (2001) Toward the Quantitative Prediction of T-
Cell Epitopes: CoMFA and CoMSIA Studies of Peptides with Affinity for the
Class I MHC Molecule HLA-A*0201. J Med Chem 44: 3572–3581.
7. Guan P, Doytchinova IA, Flower DR (2003) HLA-A3 supermotif defined by
quantitative structure-activity relationship analysis. Protein Eng 16: 11–18.
8. Hattotuwagama CK, Guan P, Doytchinova IA, Flower DR (2004) New
Horizons In Mouse Immunoinformatics: Reliable In Silico Prediction Of Mouse
Class I Histocompatibility Major Complex Peptide Binding Affinity. Org Biomol
Chem 2: 3274–3283.
9. Korber B, LaBute M, Yusim K (2006) Immunoinformatics comes of age. PLoS
Comput Biol 2: e71.
10. Doytchinova IA, Walshe VA, Jones NA, Gloster SE, Borrow P, et al. (2004)
Coupling In Silico and In Vitro Analysis of Peptide-MHC Binding: A
Bioinformatic Approach Enabling Prediction of Superbinding Peptides and
Anchorless Epitopes. J Immunol 172: 7495–7502.
11. Blythe MJ, Doytchinova IA, Flower DR (2002) JenPep: a database of
quantitative functional peptide data for immunology. Bioinformatics 18:
434–439.
12. McSparron H, Blythe MJ, Zygouri C, Doytchinova IA, Flower DR (2003)
JenPep: A Novel Computational Information Resource for Immunobiology and
Vaccinology. J Chem Inf Comput Sci 43: 1276–1287.
13. Toseland CP, Clayton DJ, McSparron H, Hemsley SL, Blythe MJ, et al. (2005)
AntiJen: a quantitative immunology database integrating functional, thermody-
namic, kinetic, biophysical, and cellular data. Immunome Research 1: 4.
14. Doytchinova IA, Guan P, Flower DR (2004) Quantitative Structure Activity
Relationships and the prediction of MHC supermotifs. Methods 34: 444–453.
15. Doytchinova IA, Flower DR (2003) Towards the in silico identification of class II
restricted T-cell epitopes: a partial least squares iterative self-consistent algorithm
for affinity prediction. Bioinformatics 19: 2263–2270.
16. Guan P, Doytchinova IA, Zygouri C, Flower DR (2003) MHCPred: a server for
quantitative prediction of peptide-MHC binding. Nucleic Acids Res 31:
3621–3624.
17. Doytchinova IA, Flower DR (2006) Class I T cell epitope prediction:
improvements using a combination of Proteasome cleavage, TAP affinity, and
MHC binding. Molecular Immunology 43: 2037–2044.
18. Doytchinova IA, Guan P, Flower DR (2006) EpiJen: multistep T cell epitope
prediction. BMC Bioinformatics 7: 131.
19. Doytchinova IA, Blythe MJ, Flower DR (2002) Additive Method for the
Prediction of Protein-Peptide Binding Affinity. Application to the MHC Class I
Molecule HLA-A*0201. J Proteome Research 1 263-272.
20. Snary D, Barnstable CJ, Bodmer WF, Crumpton MJ (1977) Molecular structure
of human histocompatibility antigens: the HLA-C series. Eur J Immunol 7:
580–585.
21. Rao X, Costa AI, van Baarle D, Kesmir C (2009) A comparative study of HLA
binding affinity and ligand diversity: implications for generating immunodomi-
nant CD8+ T cell responses. J Immunol 182: 1526–1532.
22. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004)
Dominant influence of HLA-B in mediating the potential co-evolution of HIV
and HLA. Nature 432: 769–775.
23. Goulder PJ, Bunce M, Luzzi G, Phillips RE, McMichael AJ (1997) Potential
underestimation of HLA-C-restricted cytotoxic T-lymphocyte responses. AIDS
11: 1884–1886.
24. Cao J, McNevin J, McSweyn M, Liu Y, Mullins JI, et al. (2008) Novel cytotoxic
T-lymphocyte escape mutation by a three-amino-acid insertion in the human
immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with
drug resistance. J Virol 82: 495–502.
25. Yokoyama WM (2005) Natural killer cell immune responses. Immunol Res 32:
317–325.
26. Brooks AG, Boyington JC, Sun PD (2000) Natural killer cell recognition of HLA
class I molecules. Rev Immunogenet 2: 433–448.
27. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-
genome association study of major determinants for host control of HIV-1.
Science 317: 944–947.
28. Andersen MH, Søndergaard I, Zeuthen J, Elliott T, Haurum JS (1999) An assay
for peptide binding to HLA-Cw*0102. Tissue Antigens 54: 185–190.
29. Barber LD, Percival L, Valiante NM, Chen L, Lee C, et al. (1996) The inter-
locus recombinant HLA-B*4601 has high selectivity in peptide binding and
functions characteristic of HLA-C. J Exp Med 184: 735–740.
30. Schuler MM, Nastke MD, Stevanovikc´ S (2007) SYFPEITHI: database for
searching and T-cell epitope prediction. Methods Mol Biol 409: 75–93.
31. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, et al. (2006) Selection on the
Human Immunodeficiency Virus Type 1 Proteome following Primary Infection.
J Virol 80: 9519–9529.
32. Tong JC, Zhang ZH, August JT, Brusic V, Tan TW, et al. (2007) In silico
characterization of immunogenic epitopes presented by HLA-Cw*0401.
Immunome Res 3: 7.
33. Lundegaard C, Lund O, Nielsen M (2008) Accurate approximation method for
prediction of class I MHC affinities for peptides of length 8, 10 and 11 using
prediction tools trained on 9mers. Bioinformatics 24: 1397–1378.
34. Doytchinova IA, Guan P, Flower DR (2004) Identifiying Human Major
Histocompatibility Complex Supertypes Using Bioinformatic Methods,
J Immunol 172: 4314–4323.
35. Lundegaard C, LamberthK, HarndahlM, Buus S, LundO, et al. (2008) NetMHC-
3.0: accurate web accessible predictions of human, mouse and monkeyMHC class I
affinities for peptides of length 8-11. Nucleic Acids Res 36: W509–512.
36. Lopes AR, Jaye A, Dorrell L, Sabally S, Alabi A, et al. (2003) Greater CD8(+)
TCR Heterogeneity and Functional Flexibility in HIV-2 Compared to HIV-1
Infection. J Immunol 171: 307–316.
37. Wilson IA, Fremont DH (1993) Structural analysis of MHC class I molecules
with bound peptide antigens. Semin Immunol 5: 75–80.
38. Willett P (1995) Genetic algorithms in molecular recognition and design. Trends
Biotechnol 13: 516–521.
39. Doytchinova IA, Flower DR (2007) Predicting class I major histocompatibility
complex (MHC) binders using multivariate statistics: comparison of discriminant
analysis and multiple linear regression. J Chem Inf Model 47: 234–238.
40. Flower DR (1998) DISSIM: a program for the analysis of chemical diversity.
J Mol Graph Model 16: 239–253.
41. Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, et al. (2007) HIV
Molecular Immunology 2006/2007, Los Alamos, New Mexico: Los Alamos
National Laboratory, Theoretical Biology and Biophysics. LA-UR 07-4752.
42. Doytchinova IA, Flower DR (2005) In Silico Identification of Supertypes for
Class II MHCs. J Immunol 174: 7085–7095.
43. Zhang H, Lundegaard C, Nielsen M (2009) Pan-specific MHC class I predictors:
a benchmark of HLA class I pan-specific prediction methods. Bioinformatics 25:
83–89.
44. Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, et al. (2009) NetMHCpan, a
method for MHC class I binding prediction beyond humans. Immunogenetics
61: 1–13.
45. Wan S, Coveney PV, Flower DR (2005) Molecular Basis of Peptide Recognition
by the T-Cell Receptor: Affinity differences calculated using large scale
computing. J Immunol 175: 1715–1723.
46. Knapp B, Omasits U, Frantal S, Schreiner W (2009) A critical cross-validation of
high throughput structural binding prediction methods for pMHC. J Comput
Aided Mol Des 23: 301–307.
47. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, et al. (1993) Prominent role
of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell
74: 929–937.
48. Davies MN, Hattotuwagama CK, Moss DS, Drew MGB, Flower DR (2006)
Statistical deconvolution of enthalpic energetic contributions to MHC-peptide
binding affinity. BMC Structural Biology 6: 5.
49. Calderone CT, Williams DH (2001) An enthalpic component in cooperativity:
the relationship between enthalpy, entropy, and noncovalent structure in weak
associations. J Am Chem Soc 123: 6262–6267.
50. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature
455: 613–619.
51. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320: 760–764.
52. Streeck H, Li B, Poon AF, Schneidewind A, Gladden AD, et al. (2008) Immune-
driven recombination and loss of control after HIV superinfection. J Exp Med
205: 1789–1796.
53. Mullins JI, Jensen MA (2006) Evolutionary dynamics of HIV-1 and the control
of AIDS. Curr Top Microbiol Immunol 299: 171–192.
54. Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, et al. (2001)
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute
and chronic HIV infection. J Exp Med 193: 181–194.
55. Turnbull EL, Wong M, Wang S, Wei X, Jones NA, et al. (2009) Kinetics of
expansion of epitope-specific T cell responses during primary HIV-1 infection.
J Immunol 182: 7131–7145.
56. Goulder PJ, Watkins DI (2008) Impact of MHC class I diversity on immune
control of immunodeficiency virus replication. Nat Rev Immunol 8: 619–630.
57. Boyington JC, Sun PD (2002) A structural perspective onMHC class I recognition
by killer cell immunoglobulin-like receptors. Mol Immunol 38: 1007–1021.
58. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of
natural killer cells. Nat Immunol 9: 503–510.
59. Altfeld M, Goulder P (2007) ‘Unleashed’ natural killers hinder HIV. Nat Genet
39: 708–710.
60. Thananchai H, Makadzange T, Maenaka K, Kuroki K, Peng Y, et al. (2009)
Reciprocal recognition of an HLA-Cw4-restricted HIV-1 gp120 epitope by
CD8+ T cells and NK cells. AIDS 23: 189–193.
61. Harndahl M, Justesen S, Lamberth K, Røder G, Nielsen M, et al. (2009) Peptide
binding to HLA class I molecules: homogenous, high-throughput screening, and
affinity assays. J Biomol Screen 14: 173–180.
62. Stuber G, Modrow S, Ho¨glund P, Franksson L, Elvin J, et al. (1992) Assessment
of major histocompatibility complex class I interaction with Epstein-Barr virus
and human immunodeficiency virus peptides by elevation of membrane H-2 and
HLA in peptide loading-deficient cells. Eur J Immunol 22: 2697–2703.
63. Mulder A, Kardol MJ, Uit het Broek CM, Tanke-Visser J, Young NT, et al.
(1998) A human monoclonal antibody against HLA-Cw1 and a human
monoclonal antibody against an HLA-A locus determinant derived from a
single uniparous female. Tissue Antigens 52: 393–396.
64. SYBYL6.9, distributed by Tripos Inc.
Peptide Binding to HLA-Cw*0102
PLoS ONE | www.plosone.org 11 November 2009 | Volume 4 | Issue 11 | e8095
